Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Renal Cell ◽

Free Survival ◽

Independent Review

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]

European Journal of Cancer ◽

10.1016/j.ejca.2018.09.022 ◽

2018 ◽

Vol 103 ◽

pp. 287 ◽

Cited By ~ 2

Author(s):

Toni K. Choueiri ◽

Colin Hessel ◽

Susan Halabi ◽

Ben Sanford ◽

M. Dror Michaelson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Cell Carcinoma ◽

Renal Cell ◽

Randomised Trial ◽

Initial Therapy ◽

Free Survival ◽

Independent Review

Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.4591 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 4591-4591 ◽

Cited By ~ 1

Author(s):

C. Seidel ◽

M. Fenner ◽

C. W. Reuter ◽

A. Ganser ◽

V. Gruenwald

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

Free Survival ◽

Prognostic Parameter

The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyw024 ◽

2016 ◽

Vol 46 (6) ◽

pp. 568-574 ◽

Cited By ~ 8

Author(s):

Hiroki Ishihara ◽

Tsunenori Kondo ◽

Kenji Omae ◽

Toshio Takagi ◽

Jumpei Izuka ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Renal Cell ◽

Tumor Shrinkage ◽

Second Line ◽

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy

Cancer ◽

10.1002/cncr.25750 ◽

2010 ◽

Vol 117 (12) ◽

pp. 2637-2642 ◽

Cited By ~ 57

Author(s):

Daniel Y. C. Heng ◽

Wanling Xie ◽

Georg A. Bjarnason ◽

Ulka Vaishampayan ◽

Min-Han Tan ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Renal Cell ◽

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

European Journal of Cancer ◽

10.1016/j.ejca.2018.02.012 ◽

2018 ◽

Vol 94 ◽

pp. 115-125 ◽

Cited By ~ 122

Author(s):

Toni K. Choueiri ◽

Colin Hessel ◽

Susan Halabi ◽

Ben Sanford ◽

M. Dror Michaelson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Cell Carcinoma ◽

Renal Cell ◽

Randomised Trial ◽

Initial Therapy ◽

Free Survival ◽

Independent Review

Interpreting Overall Survival (OS) Results When Progression Free Survival (PFS) Benefits Exists in Today's Oncology Landscape - Metastatic Renal Cell Carcinoma (Mrcc) Case Study

Annals of Oncology ◽

10.1016/s0923-7534(20)33940-5 ◽

2012 ◽

Vol 23 ◽

pp. ix453-ix454

Author(s):

S. Negrier ◽

Y. Tang ◽

C. Chen ◽

P. Bycott

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Cell Carcinoma ◽

Renal Cell ◽

Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC)

Annals of Oncology ◽

10.1016/s0923-7534(20)33387-1 ◽

2012 ◽

Vol 23 ◽

pp. ix270-ix271 ◽

Cited By ~ 1

Author(s):

R. Iacovelli ◽

M. Santoni ◽

G. Di Lorenzo ◽

L. Cerbone ◽

M. Aglietta ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Cell Carcinoma ◽

Targeted Therapies ◽

Renal Cell ◽

O5 Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)

European Urology Supplements ◽

10.1016/s1569-9056(13)60374-7 ◽

2012 ◽

Vol 11 (5) ◽

pp. 185-186

Author(s):

R. Iacovelli ◽

M. Milella ◽

M. Santoni ◽

G. Di Lorenzo ◽

L. Cerbone ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Cell Carcinoma ◽

Targeted Therapies ◽

Renal Cell ◽

Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: A preliminary analysis

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2011.08.010 ◽

2013 ◽

Vol 31 (7) ◽

pp. 1283-1291 ◽

Cited By ~ 16

Author(s):

Andrew D. Smith ◽

Shetal N. Shah ◽

Brian I. Rini ◽

Michael L. Lieber ◽

Erick M. Remer

Keyword(s):

Renal Cell Carcinoma ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Renal Cell ◽

Preliminary Analysis ◽

PCN23 SIMULATION AND COMPARISON OF PROGRESSION-FREE-SURVIVAL OUTCOMES OF SEQUENTIAL TARGETED THERAPY IN METASTATIC RENAL-CELL CARCINOMA

Value in Health ◽

10.1016/s1098-3015(11)71920-9 ◽

2010 ◽

Vol 13 (7) ◽

pp. A255

Author(s):

GH Mickisch ◽

B Schwander ◽

JG Cassinello ◽

J Carles ◽

S Walzer ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Renal Cell ◽

Survival Outcomes ◽